High rate of BA.1, BA.1.1 and BA.2 infection in triple vaccinated

Study cohorts

The COMMUNITY study comprises 2149 HCW at Danderyd Hospital, Stockholm, Sweden, enrolled between April and May, 2020. Study participants are followed every four months since inclusion [14-17]. SARS-CoV-2 infection prior to vaccination was confirmed by seroconversion at any of the follow-up visits and/or by PCR. All HCW were offered vaccination with either BNT162b2 (BNT) or ChAdOx1 nCoV-19 (ChAd), depending on availability, starting in January 2021. Vaccine and date of vaccination is obtained through the Swedish vaccination register (VAL Vaccinera) and data regarding PCR-confirmed SARS-CoV-2 infection is obtained through SmiNet (Swedish Public Health Agency).

To investigate serological responses to an mRNA-1273 (MOD) booster dose, 300 participants were stratified into groups depending on primary vaccine regimen and on occurrence of SARS-CoV-2 infection prior to primary vaccination. Inclusion criteria was the administration of a MOD booster dose between December 13 – 23, 2021, after primary SARS-CoV-2 vaccination with either two doses of BNT (dose interval 33-53 days) with second dose between May 23 and June 30, two doses of ChAd (dose interval 70-108 days) with second dose between May 10 and June 14, or one dose of ChAd followed by one dose of BNT (dose interval 68-115 days) with second dose between May 18 and June 21, 2021. Blood samples were collected 13 weeks (median 90 days, IQR 82-98 days) after second vaccine dose and 5 weeks (median 35 days, IQR 33-40 days) after the booster dose. Exclusion criteria was PCR-confirmed SARS-CoV-2 infection between first vaccination and up to 6 days after post booster blood sampling (n=40). Demographics are presented in Table 1.

To analyze viral characteristics and risk of breakthrough infections, we invited 375 participants shortly after their booster vaccine dose to a twice-weekly qPCR screening with self-administered naso-oropharyngeal/saliva swabs [18] for four weeks. All participants who had completed primary vaccination and received a BNT or a MOD booster were invited. Blood samples and qPCR tests were obtained at inclusion. Positive qPCR tests after a negative inclusion test were followed up by an extended set of self-administered swabs for qPCR every other day until 15 days post first positive sample. Participants that were qPCR positive at inclusion (n=21) were included in further screening but excluded from time-dependent analyses. All study participants engaged in the extended follow-up responded to a questionnaire including a pre-defined set of symptoms (fever, sore throat, cough, headache, anosmia and rhinorrea). After a 15 days completion of follow-up sampling, participants continued in the twice-weekly screening until the end of the study period. PCR, whole genome sequencing (WGS) and virus isolation was performed as previously described [19].

The study was approved by the Swedish Ethical Review Authority (dnr 2020-01653) and conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all study participants.

Serological investigation

SARS-CoV-2 anti wild-type (WT) IgG, cross-reactive IgG capable of binding omicron (BA.1, BA.1.1 and BA.2), and IgG capable of blocking WT and omicron (BA.1, BA.1.1 and BA.2) spike ACE2 binding (surrogate neutralization), were measured in post vaccination samples drawn at start of the screening study (V-PLEX SARS-CoV-2 Panel 22, 23 and 25, Meso Scale Diagnostics, Maryland, USA). Antibody titers are expressed as arbitrary units (AU)/ml, except for anti-WT IgG, which are expressed in the WHO-standard binding antibody units (BAU)/ml. An in-house calibration curve (starting dilution 1:2) was generated for the ACE2 competitive binding assay using a serum sample obtained from a previously omicron-infected study participant with a live microneutralization titer of 270 against omicron.

Live-virus microneutralization

In a sub-set of 86 participants (66 SARS-CoV-2 naïve and 20 recovered), neutralizing capacity against WT and omicron was performed using a micro-neutralization assay as previously described [20]. Briefly, heat-inactivated serum was 3-fold serially diluted, mixed with virus, incubated for 1 hour and finally added, in duplicates, to confluent Vero E6 cells in 96-well plates. Original SARS-CoV-2 WT and omicron BA.1 (both isolated from Swedish patients) were used. After 5 days incubation, the wells were inspected for signs of CPE by optical microscopy. Serum neutralizing activity was measured by 100% CPE inhibition (IC100). Each well was scored as either neutralizing (if no signs of CPE was observed) or non-neutralizing (if any CPE was observed). The arithmetic mean neutralization titer of the reciprocals of the highest neutralizing dilutions from the two duplicates for each sample was then calculated.

Statistics

Risk of breakthrough infection over four weeks screening was evaluated using survival analysis by logistic regression model adjusted for age and sex. For statistical comparisons, negative qPCR-samples were given a value of 46. Mann-Whitney U test was performed for comparisons of antibody titers between groups, peak Ct levels and number of positive days between groups, using GraphPad Prism version 9.2.0 (GraphPad Software, San Diego, California, USA).

Serological responses following MOD booster vaccine dose

We recently reported increased cross-neutralization potency against SARS-CoV-2 variants following primary vaccination with two doses BNT or heterologous ChAd followed by BNT compared to two doses of ChAd [21]. Using blood samples taken before (figure 1A) and five weeks after (figure 1B) MOD booster vaccination, we found comparable booster anti-WT spike IgG (figure 1B), anti-WT RBD IgG (figure S1A), cross-reactive IgG capable of binding omicron BA.1 spike (figure S1B) and RBD (figure S1C) and neutralizing titers against both WT (figure S1D) and omicron BA.1 (figure S1E). As previously reported [22] SARS-CoV-2 recovered vaccinees showed stronger antibody responses than SARS-CoV-2 naïve vaccinees following primary vaccination (Figure 1C). This difference still remained after the booster dose (Figure 1D), although not as strong (fold change 2.5 vs. 8.2 for anti-spike WT IgG (Figure 1D), 1.3 vs. 4.5 for cross-reactive IgG capable of binding Omicron BA.1 spike (Figure S1F), 2.7 vs. 7.6 for neutralizing titers against WT (Figure S1G) and 1.5 vs. 18 for neutralizing titers against Omicron BA.1 (Figure S1H) after booster dose as compared to after primary vaccination).

• Download figure
• Open in new tab

Figure 1. Impact of primary vaccine regimens and prior infection on booster antibody responses.

Anti-WT spike IgG three months after primary vaccination series with two doses BNT, two doses ChAd or one dose ChAd followed by one dose BNT (A), and anti-spike IgG one month after MOD booster vaccine dose in the same participants (B).

Anti-WT spike IgG in SARS-CoV-2 naïve (light blue dots) and recovered (dark blue dots) participants 3 months after primary vaccination series with two doses BNT, two doses ChAd or one dose ChAd followed by one dose BNT (C) and one month after MOD booster vaccine dose in the same participants (D). Microneutralizing titers against SARS-CoV-2 WT and omicron BA.1 in SARS-CoV-2 naïve (E) and recovered (F) participants one month after MOD booster vaccine dose. IgG titers are presented as binding antibody units (BAU)/ml and microneutralizing titers are presented as lowest neutralizing dilution (1/Y). Lines depict geometric mean titers and bars depict 95% confidence interval. S; spike, WT; wild-type, Neut; microneutralizing titer, BAU; binding antibody units; BNT; BNT162b2 mRNA vaccine, ChAd; ChAdox1 n-CoV 19 vaccine, MOD; mRNA-1273 vaccine, M; months, ns; P > 0.05, *; P ≤ 0.05, **; P ≤ 0.01, ***; P ≤ 0.001, ****; P ≤ 0.0001.

Consistent with recent reports [23-25], post booster neutralization of omicron BA.1 was substantially lower compared to neutralization of WT both in SARS-CoV-2 naïve participants (10.2 fold-change, p<0.001) (Figure 1E) and in SARS-CoV-2 recovered participants (fold change 19.2, p<0.0001) (Figure 1F).

Taken together, these findings show that while booster vaccination may level out differences due to various prior immunizations the serological responses against omicron is clearly lower than against WT SARS-CoV-2.

High rate of Omicron breakthrough infection in triple-vaccinated HCW January – February 2022

To investigate risk for post booster breakthrough infections with omicron, 375 triple-vaccinated participants were enrolled in a qPCR-screening study early 2022. Demographics and vaccine regimens are presented in Table 2. During this period, BA.1, BA.1.1 and BA.2 circulated in Sweden. Self-administered naso-oropharyngeal/saliva tests were performed twice weekly for four weeks (median adherence 2 samples per week, IQR 1.75-2). The total time-at-risk was 1485 person-weeks, total number of screening samples 2502.

A total of 82 (22% of all tested participants) omicron breakthrough infections were detected during the four-week screening period, among which 21 were detected at study inclusion. 61 participants who were negative at first sample and subsequently tested positive during the four week screening were enrolled in a 14-day follow up with self-administered samples every second day. Adherence to these follow-up samplings was high with a median of 7 (IQR 7-7) self-administered follow-up samples. Analysis of viral RNA levels revealed a peak day three after initial positive test, and that the majority of the participants were positive with Ct < 30 nine days after initial positive test (figure 2A). Six participants, all with Ct values >30 in the initial positive sample, were qPCR negative in all follow-up samples. 23 of 61 (38%) participants remained asymptomatic > 48 hours after first qPCR-positive sample, with a median pre-symptomatic Ct value of 28.9 (range 19.4-38). Six participants (9%) remained asymptomatic throughout the whole course of their infection (Figure 2B). Peak viral load and time to viral clearance was not significantly different between participants with asymptomatic course of infection and those with symptoms at any time point during the infection (p=0.06 and p=0.095, respectively).

• Download figure
• Open in new tab

Figure 2. SARS-CoV-2 omicron viral load, time to viral clearance and impact of pre infection antibody titers, symptoms and prior infection.

Ct value during the first 15 days of breakthrough infection in all qPCR positive participants (A), and in participants with an asymptomatic course of infection (B). Post booster microneutralizing titers against SARS-CoV-2 WT (C), omicron BA.1 (D) and anti-WT spike IgG (E) and in participants that remained qPCR negative and participants that tested qPCR positive during the screening period. Ct values in qPCR positive participants with pre-infection anti-WT microneutralization titers (F) and anti-WT IgG titers (G) in the lower (light grey) and upper (dark grey) quartile. Ct values in participants who were symptomatic (dark red) or asymptomatic (light red) at time of sampling (H) and in participants with (dark blue) and without (light blue) infection prior to booster vaccine dose (I). Ct; cyclic threshold, Pos; positive, neg; negative, S; spike, WT; wild-type; BAU; binding antibody units; Neut; microneutralizing titer, Low; lower, Up; upper, quart; quartile, sympt; symptom, ns; P > 0.05.

Post booster antibody titers are associated to viral load and time to clearance

To address whether individuals with breakthrough infections had lower antibody responses before infection, we compared antibody titers in samples obtained at inclusion in the qPCR screening in participants that subsequently tested positive to those that remained negative throughout the screening period. Post booster anti-WT spike IgG titers (Figure 2C) and neutralizing titers against both WT (figure 2D) and omicron BA.1 (figure 2E) were similar in those with and without subsequent breakthrough infection (p>0.05). High binding and neutralizing antibody titers were, however, associated with lower peak viral RNA levels (p=0.001) and a faster viral clearance (p<0.005) (figure 2F-G).

Symptomatology is associated to levels of viral RNA

Among the 55 participants with symptomatic infection (91%), “common cold” symptoms dominated. Presence of symptoms at time of sampling correlated to higher viral load compared to samples from asymptomatic participants (p<0.0001) (Figure 2H). There was a trend towards shorter duration of symptoms in participants with pre-infection anti-WT spike IgG titers in the upper quartile compared to the bottom quartile, but this did not reach significance (median duration of symptoms 5 vs 8 days, p=0.18). Symptoms in relation to median Ct value the initial seven days of infection are depicted in figure S2A-E. Fever, cough, headache and anosmia at any time point throughout the course of infection were associated with an increased viral load.

No significant association between prior SARS-CoV-2 infection and risk of breakthrough infection or viral load and clearance

Logistic regression revealed no significant protection against infection by SARS-CoV-2 infection prior to booster immunization (p=0.06, table S1); 23.0% of the SARS-CoV-2 naïve (n=50) and 20.4% of the SARS-CoV-2 recovered (n=32) participants became infected. Furthermore, no significant correlation between prior infection and peak viral load (p=0.59), time to viral clearance (p=0.51) or symptom duration (p=0.14) was observed (Figure 2I and S2F).

Comparisons between omicron sublineages BA.1, BA.1.1 and BA.2 breakthrough infections

As shown above (Figure 1E-F), post booster cross-reactive antibody responses capable of neutralizing omicron BA.1 were substantially lower compared to antibodies neutralizing WT SARS-CoV-2. When comparing cross-reactive antibody responses capable of neutralizing omicron sublineages we found slightly but significantly higher titers capable of neutralizing BA.2 as compared to BA.1 (Figure 3A).

• Download figure
• Open in new tab

Figure 3. Post booster cross-reactive antibody responses capable of binding and neutralizing omicron sub lineages and comparisons between subsequent omicron sub lineage breakthrough infections.

Post booster cross-reactive anti-spike IgG capable of blocking ACE-2 WT, BA.1, BA1.1 and BA.2 spike binding (A). Post booster anti-WT spike IgG titers in participants that remained qPCR negative and in participants who tested positive with BA.1, BA1.1 or BA.2 infection during the screening period (B). Ct values in qPCR positive participants the first 15 days of breakthrough infection with BA.1, BA.1.1 and BA.2 (C). Number of symptomatic days for participants who tested positive with BA.1, BA1.1 or BA.2 infection during the screening period (D). Lines depict geometric mean titers and bars depict 95% confidence interval. Pos; positive, neg; negative, S; spike, WT; wild-type; Ct; cyclic threshold, AU; arbitrary units; BAU; binding antibody units, ns; p > 0.05, *; p ≤ 0.05; **p ≤ 0.01

WGS was successful in 71/72 cases with at least one sample with Ct < 35, identifying 26 BA.1 (of which 20 were included in follow-up), 21 BA.1.1 (13 in follow-up), and 24 BA.2 (22 in follow-up) infections. Notably, pre-infection anti-WT spike IgG were comparable in participants that subsequently became infected, and those that remained qPCR negative, regardless of omicron sublineage (Figure 3B).

Median Ct value of first positive sample was 29.4 in BA.1 vs. 25 in BA.2 infections (Figure 3C), corresponding to an approximate 100-fold higher level of viral RNA in BA.2 infected individuals early in the course of infection. These differences were however not significant (p=0.06). There was also a trend towards a longer time to viral clearance in BA.2 infections as compared to BA.1 infections (p=0.13) (Figure 3C). Symptom duration was significantly longer in BA.2 infected compared to BA.1 (median duration of symptoms 8 vs 6 days), p<0.01 (Figure 3D). There were no asymptomatic cases among BA.2 infections (n=22).

Isolation of infectious viruses was successful from nine individuals (three infected with BA.1 and six with BA.1.1). Interestingly, isolation of viable viruses was possible from one sample with Ct 27 and from one sample drawn at day 9, showing that samples with relatively high Ct levels and samples from late in the course of infection can contain infectious viruses.